Literature DB >> 18817800

Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro.

James A Dykens1, Joseph Jamieson, Lisa Marroquin, Sashi Nadanaciva, Puja A Billis, Yvonne Will.   

Abstract

As a class, the biguanides induce lactic acidosis, a hallmark of mitochondrial impairment. To assess potential mitochondrial impairment, we evaluated the effects of metformin, buformin and phenformin on: 1) viability of HepG2 cells grown in galactose, 2) respiration by isolated mitochondria, 3) metabolic poise of HepG2 and primary human hepatocytes, 4) activities of immunocaptured respiratory complexes, and 5) mitochondrial membrane potential and redox status in primary human hepatocytes. Phenformin was the most cytotoxic of the three with buformin showing moderate toxicity, and metformin toxicity only at mM concentrations. Importantly, HepG2 cells grown in galactose are markedly more susceptible to biguanide toxicity compared to cells grown in glucose, indicating mitochondrial toxicity as a primary mode of action. The same rank order of potency was observed for isolated mitochondrial respiration where preincubation (40 min) exacerbated respiratory impairment, and was required to reveal inhibition by metformin, suggesting intramitochondrial bio-accumulation. Metabolic profiling of intact cells corroborated respiratory inhibition, but also revealed compensatory increases in lactate production from accelerated glycolysis. High (mM) concentrations of the drugs were needed to inhibit immunocaptured respiratory complexes, supporting the contention that bioaccumulation is involved. The same rank order was found when monitoring mitochondrial membrane potential, ROS production, and glutathione levels in primary human hepatocytes. In toto, these data indicate that biguanide-induced lactic acidosis can be attributed to acceleration of glycolysis in response to mitochondrial impairment. Indeed, the desired clinical outcome, viz., decreased blood glucose, could be due to increased glucose uptake and glycolytic flux in response to drug-induced mitochondrial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817800     DOI: 10.1016/j.taap.2008.08.013

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  84 in total

1.  Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Authors:  Joshua Kilgore; Amanda L Jackson; Leslie H Clark; Hui Guo; Lu Zhang; Hannah M Jones; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.

Authors:  Anja Bastian; Jessica E Thorpe; Bryan C Disch; Lora C Bailey-Downs; Aleem Gangjee; Ravi K V Devambatla; Jim Henthorn; Kenneth M Humphries; Shraddha S Vadvalkar; Michael A Ihnat
Journal:  J Pharmacol Exp Ther       Date:  2015-02-26       Impact factor: 4.030

4.  Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration.

Authors:  S Larsen; R Rabøl; C N Hansen; S Madsbad; J W Helge; F Dela
Journal:  Diabetologia       Date:  2011-10-19       Impact factor: 10.122

5.  Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel.

Authors:  Jing Li; Ling Chen; Qiuli Liu; Mei Tang; Yuan Wang; Jinjin Yu
Journal:  Cancer Biol Ther       Date:  2018-02-27       Impact factor: 4.742

6.  Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics.

Authors:  Ubaldo E Martinez-Outschoorn; Marco Prisco; Adam Ertel; Aristotelis Tsirigos; Zhao Lin; Stephanos Pavlides; Chengwang Wang; Neal Flomenberg; Erik S Knudsen; Anthony Howell; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

7.  Mitochondrial dysfunction induced by leflunomide and its active metabolite.

Authors:  Jiekun Xuan; Zhen Ren; Tao Qing; Letha Couch; Leming Shi; William H Tolleson; Lei Guo
Journal:  Toxicology       Date:  2018-02-08       Impact factor: 4.221

8.  Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication.

Authors:  Alessandro Protti; Riccarda Russo; Paola Tagliabue; Sarah Vecchio; Mervyn Singer; Alain Rudiger; Giuseppe Foti; Anna Rossi; Giovanni Mistraletti; Luciano Gattinoni
Journal:  Crit Care       Date:  2010-02-19       Impact factor: 9.097

9.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

10.  Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites.

Authors:  Peizhou Jiang; Ming Gan; Abdul Shukkur Ebrahim; Monica Castanedes-Casey; Dennis W Dickson; Shu-Hui C Yen
Journal:  Neurobiol Aging       Date:  2012-11-28       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.